Oncologist Lauds Imfinzi as Trailblazer in Stage III Lung Cancer, Eagerly Awaiting OS Data

Prof. Kazuhiko Nakagawa, Department of Medical Oncology, Kinki University Faculty of Medicine The debut of AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will bring a bigger impact to the Stage III lung cancer space than what leading PD-1 products have done for...read more